Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, Wenhua, Guan, Weijie, Chen, Ruchong, Wang, Wei, Li, Jianfu, Xu, Ke, Li, Caichen, Ai, Qing, Lu, Weixiang, Liang, Hengrui, Li, Shiyue, He, Jianxing
Published in The Lancet Oncology (01.03.2020)
Published in The Lancet Oncology (01.03.2020)
Get full text
Journal Article
Web Resource
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle, Aurélien, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller, Wilson H, Italiano, Antoine, Kao, Steven, Piha-Paul, Sarina A, Delord, Jean-Pierre, McWilliams, Robert R, Fabrizio, David A, Aurora-Garg, Deepti, Xu, Lei, Jin, Fan, Norwood, Kevin, Bang, Yung-Jue
Published in The lancet oncology (01.10.2020)
Published in The lancet oncology (01.10.2020)
Get full text
Journal Article
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno
Published in The lancet oncology (01.01.2022)
Published in The lancet oncology (01.01.2022)
Get full text
Journal Article
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
Maringe, Camille, Spicer, James, Morris, Melanie, Purushotham, Arnie, Nolte, Ellen, Sullivan, Richard, Rachet, Bernard, Aggarwal, Ajay
Published in The Lancet Oncology (01.08.2020)
Published in The Lancet Oncology (01.08.2020)
Get full text
Journal Article
Web Resource
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Ren, Zhenggang, Xu, Jianming, Bai, Yuxian, Xu, Aibing, Cang, Shundong, Du, Chengyou, Li, Qiu, Lu, Yinying, Chen, Yajin, Guo, Yabing, Chen, Zhendong, Liu, Baorui, Jia, Weidong, Wu, Jian, Wang, Junye, Shao, Guoliang, Zhang, Bixiang, Shan, Yunfeng, Meng, Zhiqiang, Wu, Jianbing, Gu, Shanzhi, Yang, Wei, Liu, Chao, Shi, Xuetao, Gao, Zhenyuan, Yin, Tao, Cui, Jiuwei, Huang, Ming, Xing, Baocai, Mao, Yilei, Teng, Gaojun, Qin, Yanru, Wang, Jinhai, Xia, Feng, Yin, Guowen, Yang, Yong, Chen, Mingxia, Wang, Yan, Zhou, Hui, Fan, Jia
Published in The lancet oncology (01.07.2021)
Published in The lancet oncology (01.07.2021)
Get full text
Journal Article
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Schmid, Peter, Rugo, Hope S, Adams, Sylvia, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Maiya, Vidya, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A
Published in The lancet oncology (01.01.2020)
Published in The lancet oncology (01.01.2020)
Get full text
Journal Article
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Monin, Leticia, Laing, Adam G, Muñoz-Ruiz, Miguel, McKenzie, Duncan R, del Molino del Barrio, Irene, Alaguthurai, Thanussuyah, Domingo-Vila, Clara, Hayday, Thomas S, Graham, Carl, Seow, Jeffrey, Abdul-Jawad, Sultan, Kamdar, Shraddha, Harvey-Jones, Elizabeth, Graham, Rosalind, Cooper, Jack, Khan, Muhammad, Vidler, Jennifer, Kakkassery, Helen, Sinha, Shubhankar, Davis, Richard, Dupont, Liane, Francos Quijorna, Isaac, O'Brien-Gore, Charlotte, Lee, Puay Ling, Eum, Josephine, Conde Poole, Maria, Joseph, Magdalene, Davies, Daniel, Wu, Yin, Swampillai, Angela, North, Bernard V, Montes, Ana, Harries, Mark, Rigg, Anne, Spicer, James, Malim, Michael H, Fields, Paul, Patten, Piers, Di Rosa, Francesca, Papa, Sophie, Tree, Timothy, Doores, Katie J, Hayday, Adrian C, Irshad, Sheeba
Published in The lancet oncology (01.06.2021)
Published in The lancet oncology (01.06.2021)
Get full text
Journal Article
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, Cappuzzo, Federico
Published in The lancet oncology (01.07.2019)
Published in The lancet oncology (01.07.2019)
Get full text
Journal Article
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
O’Brien, Mary, Paz-Ares, Luis, Marreaud, Sandrine, Dafni, Urania, Oselin, Kersti, Havel, Libor, Esteban, Emilio, Isla, Dolores, Martinez-Marti, Alex, Faehling, Martin, Tsuboi, Masahiro, Lee, Jong-Seok, Nakagawa, Kazuhiko, Yang, Jing, Samkari, Ayman, Keller, Steven M, Mauer, Murielle, Jha, Nitish, Stahel, Rolf, Besse, Benjamin, Peters, Solange
Published in The lancet oncology (01.10.2022)
Published in The lancet oncology (01.10.2022)
Get full text
Journal Article
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W
Published in The lancet oncology (01.05.2021)
Published in The lancet oncology (01.05.2021)
Get full text
Journal Article
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Hong, David S, DuBois, Steven G, Kummar, Shivaani, Farago, Anna F, Albert, Catherine M, Rohrberg, Kristoffer S, van Tilburg, Cornelis M, Nagasubramanian, Ramamoorthy, Berlin, Jordan D, Federman, Noah, Mascarenhas, Leo, Geoerger, Birgit, Dowlati, Afshin, Pappo, Alberto S, Bielack, Stefan, Doz, François, McDermott, Ray, Patel, Jyoti D, Schilder, Russell J, Tahara, Makoto, Pfister, Stefan M, Witt, Olaf, Ladanyi, Marc, Rudzinski, Erin R, Nanda, Shivani, Childs, Barrett H, Laetsch, Theodore W, Hyman, David M, Drilon, Alexander
Published in The lancet oncology (01.04.2020)
Published in The lancet oncology (01.04.2020)
Get full text
Journal Article
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi
Published in The lancet oncology (01.02.2019)
Published in The lancet oncology (01.02.2019)
Get full text
Journal Article
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I
Published in The lancet oncology (01.12.2020)
Published in The lancet oncology (01.12.2020)
Get full text
Journal Article
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, Cruz-Bermúdez, Alberto
Published in The lancet oncology (01.11.2020)
Published in The lancet oncology (01.11.2020)
Get full text
Journal Article
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Zhu, Andrew X, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Webber, Andrea L, Ebbinghaus, Scot W, Ma, Junshui, Siegel, Abby B, Cheng, Ann-Lii, Kudo, Masatoshi, Alistar, Angela, Asselah, Jamil, Blanc, Jean-Frederic, Borbath, Ivan, Cannon, Timothy, Chung, Ki, Cohn, Allen, Cosgrove, David P, Damjanov, Nevena, Gupta, Mukul, Karino, Yoshivasu, Karwal, Mark, Kaubisch, Andreas, Kelley, Robin, Van Laethem, Jena-Luc, Larson, Timothy, Lee, James, Li, Daneng, Manhas, Atisha, Manji, Gulam Abbas, Numata, Kazushi, Parsons, Benjamin, Paulson, Andrew S., Pinto, Carmine, Ramirez, Robert, Ratnam, Suresh, Rizell, Magnus, Rosmorduc, Olivier, Sada, Yvonne, Sasaki, Yutaka, Stal, Per I, Strasser, Simone, Trojan, Joerg, Vaccaro, Gina, Van Vlierberghe, Hans, Weiss, Alan, Weiss, Karl-Heinz, Yamashita, Tatsuya
Published in The lancet oncology (01.07.2018)
Published in The lancet oncology (01.07.2018)
Get full text
Journal Article
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, Boku, Narikazu
Published in The lancet oncology (01.02.2022)
Published in The lancet oncology (01.02.2022)
Get full text
Journal Article
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, Thomas, Oudard, Stephane, Vulsteke, Christof, Fléchon, Aude, Yu, Evan Y, Imai, Kentaro, Homet Moreno, Blanca, Alva, Ajjai, Lazzaro, Mauricio Fernandez, Gatica, Gabriela, Van Aelst, Filip, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Soares, Joao Paulo Holanda, Cheng, Susanna, Leal, Jose Luis, Ibanez, Carolina, Laguerre, Brigitte, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Gravis, Gwenaelle, Reichardt, Peter, Herden, Jan, Pfister, David, Niegisch, Guenter, Boegemann, Martin, Gakis, Georgios, Neisius, Andreas, Thomas, Christian, Kosa, Judit Erzsebet, Bodoky, Gyorgy, Geczi, Lajos, Frank, Stephen Jay, Kejzman, Daniel, Rosenbaum, Eli, Rouvinov, Keren, Arai, Gaku, Takayama, Tatsuya, Fujimoto, Kiyohide, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Takano, Toshimi, Joraku, Akira, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Beerepoot, Laurens, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Karlov, Petr Alexandrovich, Cohen, Graham Lawrence, Ruff, Paul, Lee, Nari, Rodriguez-Vida, Alejo, Grande, Enrique, Munoz Langa, Jose, Montesa Pino, Alvaro, Su, Wen-Pin, Chang, Yen-Hwa, Huang, Yi-Hsiu, Srimuninnimit, Vichien, Abali, Huseyin, Sendur, Mehmet Ali Nahit, Ozguroglu, Mustafa, Ozdogan, Mustafa, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Schlegel, Peter, Mamtani, Ronac, Wallace, James, Suh, Jason Jung-Gon, Burgess, Earle, Wong, John, Chaudhry, Arvind, Thomas, Christian A, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Joshi, Monika, Bolemon, Britt H, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Courtright, Jay G, Doshi, Gurjyot, Sartor, Oliver Alton, Mannuel, Heather D, Alva, Ajjai, Charles, Anthony, Ades, Steven, Yu, Evan, Fleming, Mark
Published in The lancet oncology (01.07.2021)
Published in The lancet oncology (01.07.2021)
Get full text
Journal Article
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Okada, Morihito, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Kodani, Mamoru, Kitagawa, Yuko
Published in The lancet oncology (01.11.2019)
Published in The lancet oncology (01.11.2019)
Get full text
Journal Article
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Cazier, Jean-Baptiste, Briggs, Sarah E W, Bisht, Vartika, Campton, Naomi A, Collins, Graham, Curley, Helen M, Earwaker, Philip, Hartley, Simon, Kerr, David, Lee, Alvin J X, Lee, Rebecca J, Lee, Siow Ming, Mckenzie, Hayley, Murugaesu, Nirupa, Powles, Thomas, Protheroe, Emily A, Purshouse, Karin, Sharma-Oates, Archana, Smith, Ashley J, Topping, Oliver, Turnbull, Chris D, Kerr, Rachel, Bedair, Ahmed, Akingboye, Akinfemi, Maynard, Alec, Pawsey, Alexander, Suwaidan, Ali Abdulnabi, Okines, Alicia, Massey, Alison, Angelakas, Angelos, Wu, Anjui, Tivey, Ann, Armstrong, Anne, Pillai, Annet, Poon-King, Ashley, Usborne, Caroline, Thirlwell, Christina, Mitchell, Christian, Sng, Christopher, Scrase, Christopher, Jingree, Christopher, Brunner, Clair, Fuller, Claire, Barrington, Craig, Muller, Daniel, Ottaviani, Diego, Gilbert, Duncan, Tacconi, Eliana, Copson, Ellen, Renninson, Emily, Burke, Emma, Smith, Fiona, Holt, Francesca, Soosaipillai, Gehan, Boyce, Hayley, Hollis, Helen, Bowyer, Helen, Illingworth, Jack, Gibson, Jack, Bhosle, Jaishree, Best, James, Sacco, Joseph, Chacko, Joseph, Cammaert, Lauren, Melcher, Lucinda, Cook, Lucy, Hewish, Madeleine, Baxter, Mark, Fittall, Matthew, Tilby, Michael, Rowe, Michael, Galazi, Myria, Sheikh, Omar, Ramage, Paul, Leonard, Pauline, Naksukpaiboon, Piangfan, Sharkey, Rachel, Bolton, Rachel, Sargent, Rebecca, Jyothirmayi, Rema, Goldstein, Robert, Oakes, Roderick, Kanani, Ruhi, Pettengell, Ruth, Massalha, Samah, Kathirgamakarthigeyan, Sangary, Dolly, Saoirse, Derby, Sarah, Lowndes, Sarah, Benafif, Sarah, Brown, Sean, Ellis, Shawn, Pugh, Sian, Shamas, Simon, Wong, Yien Ning Sophia, Tillet, Tania, Rabbi, Taslima, Angelis, Vasileios, Brown, Victoria, Hudson, Zoe
Published in The Lancet Oncology (01.10.2020)
Published in The Lancet Oncology (01.10.2020)
Get full text
Journal Article
Web Resource
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Poltoratskiy, Artem, Ponce, Santiago, Bondarenko, Igor, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Paz-Ares, Luis, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Özgüroglu, Mustafa, Conev, Nikolay, Burghuber, Otto, Moiseenko, Vladimir, Reinmuth, Niels, Ursol, Grygorii, Pajkos, Gábor, Verderame, Francesco, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Somfay, Attila, Roila, Fausto, Urda, Michal, Majem Tarruella, Margarita, Bettini, Anna Cecilia, Okamoto, Isamu, Mandziuk, Slawomir, Domine Gomez, Manuel, Wu, Shang-Yin, Knoble, Jeanna, Venkova, Violetka, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Telekes, András, Kanda, Shintaro, Nakahara, Yasuharu, Lin, Sheng-Hao, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Kultan, Juraj, Kolek, Vitezslav, Lee, Kyung Hee, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Stilwill, Joseph, De Marchi, Pedro Rafael Martins, Krasteva, Rositsa, Koubkova, Leona, Grohe, Christian, Heching, Norman Isaac, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Ganea, Doina, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Hsia, Te-Chun, Lee, Kang-Yun, Zarba, Juan Jose, Pastor, Andrea Viviana, Zukin, Mauro, Calabrich, Aknar, Dudov, Asen, Lang, Susanne, Kanazawa, Kenya, Hiltermann, Jeroen, Shparyk, Yaroslav, Kryzhanivska, Anna, Jamil, Rodney, Williamson, Michael, Han, Zhigang, Wang, Mengzhao, Li, Wei, Feng, Jifeng, Zhou, Xiangdong, Hu, Yi, Nan, Kejun, Zhang, Wei, Lin, Zhong
Published in The lancet oncology (01.01.2021)
Published in The lancet oncology (01.01.2021)
Get full text
Journal Article